BPC-157: What the Research Actually Shows About This Healing Peptide

What it is

BPC-157 is a lab-made peptide, a short chain of 15 amino acids, copied from a larger protein found in human stomach juice. Researchers at the University of Zagreb first described it in the early 1990s. The name stands for Body Protection Compound.

The parent protein appears to protect and repair the lining of the gut. BPC-157 is a stable piece of it, chosen because it resists being broken down. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

It does not work through growth hormone, which sets it apart from peptides like CJC-1295 and ipamorelin. This page reviews the research. It is not a treatment guide, and BPC-157 is not approved for human use anywhere.

What it is studied for

Almost all the research is on healing. In animals, BPC-157 has been tested on tendons, ligaments, muscle, bone, nerves, skin wounds, and the lining of the gut. The gut work is the largest body of evidence, which fits where the peptide comes from.

Researchers have also tested it against damage from NSAIDs, the common painkillers such as aspirin and diclofenac, and for inflammation more broadly. None of these uses has been confirmed in a human trial.

What the evidence actually shows

In humans

There is no published human evidence. After three decades of animal research, no peer-reviewed human trial of BPC-157 exists. A Phase I trial for inflammatory bowel disease, under the names “PL 14736” or “PL-10”, was reportedly run, but its results never appeared in a journal. That silence should weigh on everything below.

In animals

Rats with a cut Achilles tendon healed stronger, with better-organized collagen, when given BPC-157 into the abdominal cavity (Staresinic et al., 2003). Collagen is the fibrous protein that gives tendons their strength.

In rats with a crushed thigh muscle, 10 micrograms per kilogram of body weight sped up recovery and produced organized muscle fibers instead of scar (Pevec et al., 2010). Several labs have seen similar tendon and muscle results, which makes the animal case stronger than any single study.

The gut evidence is the deepest. In rats, BPC-157 reduced damage in models of colitis and countered stomach and intestinal lesions caused by diclofenac, aspirin, and other NSAIDs. It also sped healing of an inflamed esophagus and helped close fistulas, which are abnormal tunnels between organs (Sikiric et al., 2016).

A separate review covers its protection of the stomach lining against alcohol and other toxic agents. That protection runs through the mucous barrier and through prostaglandins, the local signals that manage inflammation (Sikiric et al., 2011).

Rats with a severed peripheral nerve, meaning a nerve outside the brain and spinal cord, regrew nerve tissue from both cut ends and recovered more electrical function (Gjurasin et al., 2010). In a rat model with a gap in the bone, 10 micrograms per kilogram per day improved bone density, callus formation, and strength at two and four weeks (Krivic et al., 2006).

Cell and animal studies also suggest how it might work. BPC-157 raised levels of VEGF, a signal that tells the body to grow new blood vessels, in chicken embryo tissue and in rats with restricted blood flow (Sikiric et al., 2018). New vessels bring oxygen, nutrients, and immune cells to a wound.

It also seems to steady the nitric oxide system, a signaling gas that controls blood vessel width and inflammation, pushing back against both too much and too little of it (Sikiric et al., 2014). In a dish, tendon cells exposed to BPC-157 grew, moved, and made more type I collagen, with the effect rising with the dose (Chang et al., 2011). Other lab work reports higher levels of growth signals such as EGF and NGF, and activation of the FAK-paxillin pathway, which helps cells migrate during repair.

Whether any of this happens in a human body is unproven. Animal results often fail to translate to people.

From user reports

People who use BPC-157 mostly describe it as easy to tolerate and say it helped an injury. Those reports cannot separate the peptide from rest, physical therapy, or time, and nobody records the failures. They tell us what users believe, not what the peptide does.

How it is used in studies

Most rat studies give 10 micrograms per kilogram of body weight, either injected into the abdominal cavity or by mouth. Scaling that to an 80 kilogram human by body size gives roughly 600 to 800 micrograms, but rat-to-human scaling is a rough estimate, not a dose. The oral route works in gut studies because the peptide survives stomach acid unusually well, and some rat tendon studies delivered it in drinking water.

Online forums describe injecting 250 to 500 micrograms a day under the skin, sometimes up to 800, once or twice daily for four to eight weeks, often near the injured area. The same range is discussed for oral use in gut problems. These are user reports, not trial doses.

Vendors ship it as a freeze-dried powder. Users commonly describe mixing a 5 milligram vial with 2 milliliters of bacteriostatic water, kept refrigerated and used within three to four weeks. Our storage and reconstitution guide covers handling.

Oral or injected

For gut problems, swallowing it has a clear logic: the peptide touches the gut lining directly, even if little reaches the blood. For tendons, muscle, bone, and nerves, the animal studies mostly injected it, and that route has the stronger support.

Some rats given oral BPC-157 healed tendons anyway. Whether the peptide reached the bloodstream intact, or whether the gut signaled the rest of the body through nerves such as the vagus, is unresolved. Neither route has been tested in people. Our guide on how peptides are administered explains why routes matter.

Side effects and unknowns

Human safety data are close to nonexistent. Users report injection-site redness, mild pain, or bruising, which any injection can cause, and occasionally nausea, dizziness, or headache. The animal literature has not flagged major toxicity.

The main theoretical worry is cancer. Tumors need new blood vessels to grow, and BPC-157 encourages new vessels in animals. One study found it did not promote tumor growth in a melanoma model (Sikiric et al., 2018), but the question has not been studied properly. Anyone with an active or undiagnosed cancer has no data to lean on.

No one has published studies on reproductive harm, cancer-causing potential, drug interactions, or how the human body absorbs and clears it. That absence does not mean it is dangerous. It means we do not know.

Legal status

In the United States, BPC-157 is not FDA-approved for any use and is not a controlled substance. It is sold as a “research chemical” for lab use, and the FDA sent warning letters to some compounding pharmacies over BPC-157 products in 2023 and 2024.

Australia’s TGA listed it as a Schedule 4, prescription-only substance in 2023. In the European Union, rules vary by country; it is generally available as a research chemical and not approved for clinical use.

The World Anti-Doping Agency does not list BPC-157 by name. Peptide rules change, though, and some anti-doping bodies may treat it under broader peptide hormone provisions.

Bottom line

In rats, BPC-157 is one of the most consistently positive healing compounds ever studied. In people, it has never been tested in a published trial. Whether the rat results carry over is the whole question, and thirty years on, nobody has answered it.

Frequently Asked Questions

Does BPC-157 have any published human clinical trials?

No. As of early 2026, no peer-reviewed human trial data for BPC-157 has been published. Everything comes from animal studies, mostly in rats, and from cells in a dish.

Is BPC-157 safe?

We do not have enough data to say. Users generally describe it as easy to tolerate and the animal studies have not found major toxicity, but no human safety, absorption, or toxicology study has been published.

Can BPC-157 be taken orally?

In animals it has worked both swallowed and injected, and it survives stomach acid better than most peptides. Oral use is mainly discussed for gut problems. How much of an oral dose reaches the blood in humans has never been measured.

How does BPC-157 compare to TB-500?

They work differently. BPC-157 is studied for new blood vessel growth, nitric oxide balance, and growth signals, with effects often described as local. TB-500, a fragment of thymosin beta-4, works on actin, the scaffolding inside cells, and is studied as a whole-body healing peptide. GHK-Cu and LL-37 are also studied for wound healing through separate pathways. Our injury recovery guide compares them.

Does BPC-157 show up on drug tests?

Standard workplace panels do not test for it. Specialized peptide testing, such as the methods used in professional sports anti-doping, could detect it.

Should BPC-157 be injected near the injury site?

People who use it generally describe injecting under the skin near the injury. Animal studies have used both local and whole-body injection with positive results. No human study has compared the two.

References

1. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PubMed
2. Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157-NO-system Relation.” Curr Pharm Des. 2014;20(7):1126-35. PubMed
3. Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-80. PubMed
4. Staresinic M, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” J Orthop Res. 2003;21(6):976-83. PubMed
5. Pevec D, et al. “Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application.” Med Sci Monit. 2010;16(3):BR81-88. PubMed
6. Sikiric P, et al. “Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems.” Curr Pharm Des. 2018;24(18):1946-1956. PubMed
7. Gjurasin M, et al. “Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions.” Life Sci. 2010;82(3-4):116-22. PubMed
8. Krivic A, et al. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and target reversal.” J Orthop Res. 2006;24(5):982-9. PubMed
9. Sikiric P, et al. “Pentadecapeptide BPC 157 and the gastrointestinal tract.” Curr Med Chem. 2011;18(29):4547-56. PubMed

See also

• Peptide
  GHK-Cu (Copper Peptide): Research, Mechanism, and Evidence for Tissue Repair

  GHK-Cu is a copper-carrying peptide your body makes naturally, studied mainly as a skin cream for aging skin and, in animals, for wound healing.

• Peptide
  LL-37: What the Research Shows About This Human Antimicrobial Peptide

  LL-37 is the only cathelicidin peptide humans make, a 37-amino-acid molecule that kills bacteria directly and helps close wounds. It is well studied in the lab and in animals, and injecting it has never been tested in a person.

• Peptide
  TB-500 (Thymosin Beta-4): What the Research Shows About This Healing Peptide

  TB-500 is a lab-made copy of part of thymosin beta-4, a repair protein found in nearly every human cell, with healing evidence that comes almost entirely from animals.